EU MDR or IVDR Certification Program
The European Union replaced its medical device directives with two regulations that raised the evidence bar for nearly every device sold into the bloc. Certificates issued under the old directives expire on a staged schedule, and a device without a valid certificate cannot be placed on the market. The practical effect is that manufacturers have to re-earn approval for products that have been sold in Europe for decades, with clinical evidence, post-market surveillance plans, and technical documentation built to a standard that did not exist when those products were designed. Notified body capacity is finite, review queues are long, and the deadlines have already been extended once because the system could not absorb the volume. For a manufacturer, this is a multi-year program consuming regulatory, clinical, and quality capacity, and it forces decisions about which products are worth keeping. Every part of it — the certificates, the registrations, the hiring, the portfolio pruning — leaves a public trace. Avina reads it.
Why an EU Device Recertification Program Is a Buying Signal
The regulations changed the nature of the work rather than merely the paperwork. Clinical evaluation now requires evidence that many legacy devices never generated, because they were approved under a framework that permitted equivalence to a predicate. Post-market surveillance became a continuous obligation with periodic reporting rather than a complaint-handling function. Technical documentation has to be assembled and maintained to a structure that most legacy files do not follow. Each of those is a system, not a document, and companies that ran the old regime on shared drives and spreadsheets discover quickly that the new one cannot be run that way. That produces a recognizable purchasing pattern. Regulatory information management to track products, certificates, registrations, and submission status across markets. Clinical evaluation and literature management, because the evidence requirement is recurring rather than one-time. Post-market surveillance and vigilance systems to collect, analyze, and report field data on a schedule. Quality management software, because the audit intensity increased and paper-based quality systems fail audits. Unique device identification and labeling infrastructure to support registration. And a significant volume of external consulting, because the internal capacity does not exist. Capacity constraint creates urgency that vendors can use honestly. Notified bodies have limited reviewer capacity, queues are long, and a manufacturer that submits late may not get reviewed before its certificate expires. Companies therefore work backward from the notified body's queue rather than from the regulatory deadline, which pulls the internal work forward by many months relative to what the published dates suggest. The portfolio decision is the part most vendors miss and the part that most changes account value. Recertifying a device costs a fixed amount regardless of how much revenue it generates, so every manufacturer runs the arithmetic and discontinues the products that cannot carry the cost. A company in the middle of that analysis is deciding not only how to comply but what it will still sell in Europe in three years, and it is unusually receptive to anything that lowers the per-product cost of compliance, because lowering that cost directly changes which products survive. Smaller manufacturers feel this hardest. A large company absorbs the program into an existing regulatory organization. A company with a few dozen products and a small regulatory team faces a workload that can exceed its total annual capacity, and it either buys tooling, buys services, or leaves the market.
How Does Avina Detect Device Recertification Programs?
Avina, an AI-powered GTM platform, tracks this from both the regulatory record and the operating evidence that surrounds it. Certification milestones are publicized: manufacturers announce when a device or a product family receives a certificate under the new regulations, because it is competitively meaningful and because customers and distributors need to know. Avina captures these announcements and builds a view of how far through its portfolio each manufacturer has progressed. Registration data establishes footprint. The European device database records manufacturers, authorized representatives, importers, and registered devices with their identifiers. Avina reads registration and identifier activity to determine which companies are actively registering products, which are expanding their registered portfolio, and which have registered only a fraction of what they sell. Disclosure language reveals status and strain. Annual reports, investor presentations, and risk factors describe transition progress, notified body relationships, expected certification timing, and — importantly — the products a company has decided to discontinue in Europe rather than recertify. Avina extracts these statements and separates a company that is on schedule from one that is describing capacity risk in its own filings. Discontinuation and withdrawal notices are the most operationally useful evidence. When a manufacturer notifies customers that a product will no longer be available in European markets, it has made the portfolio decision, which identifies both a company under cost pressure and, separately, the customers who now need a replacement. Hiring shows the program is real and where it sits. Job listings for European regulatory affairs, clinical evaluation writers, post-market surveillance specialists, quality engineers, and the designated person responsible for regulatory compliance are the clearest evidence of an active program. Avina reads the mix to estimate stage: clinical evaluation and technical documentation roles during preparation, submission and notified body liaison roles during review, and post-market surveillance and vigilance roles once certificates are granted and ongoing obligations begin. Service relationships add corroboration. Engagements with regulatory consultancies, notified body announcements about capacity and designations, and conference and webinar participation indicate which manufacturers are actively working the problem. Each account is enriched with the portfolio size, the certification progress, the registration footprint, the disclosed transition position, any discontinuation decisions, and the hiring pattern, then matched against your ICP filters.
What Happens When an EU Device Regulation Signal Fires?
Avina scores the account on portfolio size relative to regulatory headcount, certification progress against the remaining timeline, and whether the company's own disclosures acknowledge capacity or schedule risk. The highest-scoring accounts are mid-sized manufacturers with broad portfolios and small regulatory teams, because their workload-to-capacity ratio is worst and their need for leverage is greatest. Routing follows program stage. Early-stage accounts route to regulatory information management, gap assessment, and technical documentation tooling. Accounts in active clinical evaluation route to literature management, evidence generation, and clinical data systems. Accounts in submission and review route to submission management and notified body coordination. Accounts with certificates in hand route to post-market surveillance, vigilance, and periodic reporting, which is where the obligation becomes permanent and the tooling requirement becomes recurring rather than project-based. Accounts publicly discontinuing products route to cost-reduction messaging, and their discontinuation notices route separately as displacement opportunities for competing manufacturers. Contacts are enriched with verified emails, phone numbers, and LinkedIn profiles through waterfall enrichment. Avina identifies the vice president of regulatory affairs and the European regulatory lead, the designated person responsible for regulatory compliance, the quality leadership who own the management system, the clinical affairs leadership responsible for evaluation and evidence, and the commercial leadership for Europe whose revenue depends on which certificates arrive on time. Reps receive a Slack alert with the certification progress, the registration footprint, the disclosed transition status, the hiring evidence, and any announced discontinuations. Salesforce and HubSpot records carry the program timeline, which runs for years and requires the account to be worked across several budget cycles rather than a single quarter. Qualified accounts can be auto-enrolled into Outreach or Salesloft sequences. The opening that works in this category is narrow and unglamorous. Regulatory teams in the middle of a transition program are not evaluating platforms in the abstract; they are trying to get a specific submission out before a notified body slot closes. Messaging that addresses the immediate constraint — the evidence gap, the documentation backlog, the surveillance reporting that starts the moment a certificate is granted — reaches people who have no attention left for anything broader, and it is the version of the pitch that survives contact with a team working to a queue it does not control.
Start Tracking EU Device Regulation Programs With Avina
Recertifying a device portfolio is a multi-year program with a hard expiry date attached to every legacy certificate. Activate this signal in Avina's Signals Library. Every plan includes a 7-day free trial with no credit card required.